GlassScriptPhysician profile
Jennifer Willene Venuk
NPI 1699448027
$1,391.33
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $431 · 2023: $726 · 2024: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.00 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $155.83 | 2022-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $124.83 | 2022 | |
| Janssen Biotech, INC. | $121.04 | 2022-2024 | Darzalex, Tecvayli |
| Incyte Corporation | $106.30 | 2023 | Jakafi |
| Daiichi Sankyo INC. | $78.66 | 2022-2024 | Injectafer, Enhertu |
| Celgene Corporation | $78.54 | 2023 | Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $75.24 | 2023-2024 | Calquence, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $72.81 | 2022-2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $70.24 | 2023 | Kisqali |
| Merck Sharp & Dohme LLC | $61.31 | 2023 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $59.50 | 2023 | |
| Genzyme Corporation | $54.46 | 2024 | |
| Genentech USA, INC. | $39.63 | 2023 | Tecentriq, Alecensa, Gavreto |
| Mirati Therapeutics, INC. | $32.44 | 2024 | Krazati |
| Jazz Pharmaceuticals INC. | $27.33 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $20.89 | 2023 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $19.68 | 2024 | Ninlaro |
| Pharmaessentia USA Corporation | $19.45 | 2023 | Besremi |
| Puma Biotechnology, INC. | $19.09 | 2023 | |
| Array Biopharma INC | $18.65 | 2023 | Mektovi, Xalkori, Lorbrena |
| Inogen, INC. | $18.59 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Beigene USA, INC. | $18.32 | 2024 | Brukinsa |
| Gilead Sciences, INC. | $17.60 | 2022 | |
| Pfizer INC. | $17.21 | 2022 | |
| Exelixis INC. | $16.88 | 2024 | Cabometyx |
| Morphosys, US INC. | $16.27 | 2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $15.45 | 2023 | Monoferric |
| Alexion Pharmaceuticals, INC. | $15.09 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Venuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.